Literature DB >> 12748508

Stage-based treatment of twin-twin transfusion syndrome.

Rubén A Quintero1, Jan E Dickinson, Walter J Morales, Patricia W Bornick, Carlos Bermúdez, Robert Cincotta, Fung Yee Chan, Mary H Allen.   

Abstract

OBJECTIVE: The purpose of this study was to compare the outcomes of patients with twin-twin transfusion syndrome who were treated with either serial amniocentesis or selective laser photocoagulation of communicating vessels according to disease severity (stage). STUDY
DESIGN: Centers that were experienced in the treatment of twin-twin transfusion syndrome were invited to share stage-based perinatal outcome data. All patients met basic standard sonographic criteria for twin-twin transfusion syndrome (polyhydramnios maximum vertical pocket, > or =8 cm; oligohydramnios maximum vertical pocket, < or =2 cm). Gestational age at first treatment was <27 weeks of gestation.
RESULTS: Three centers submitted stage-based data, for a total of 173 patients (serial amniocentesis, 78 patients from all 3 centers) and 95 selective laser photocoagulation of communicating vessels (1 center). The distribution of patients by stage was similar in the two groups. Successful pregnancy outcome (at least 1 surviving infant) was correlated inversely with stage in the serial amniocentesis but not in the selective laser photocoagulation of communicating vessels group and was significantly lower in the serial amniocentesis (66.7%) than in the selective laser photocoagulation of communicating vessels group (83.2%). Neurologic morbidity was related directly to stage in the serial amniocentesis group but not in the selective laser photocoagulation of communicating vessels group and was significantly higher in the serial amniocentesis (24.4%) than in the selective laser photocoagulation of communicating vessels (4.2%) group. Intact neurologic survival (at least 1 surviving infant without neurologic morbidity) was significantly lower in the serial amniocentesis group than in the selective laser photocoagulation of communicating vessel group (51.3% vs 78.9%), particularly in stage III and stage IV (23.5% vs 72.7% in stage IV). Patients who were treated with selective laser photocoagulation of communicating vessels were 2.4 times more likely to have at least one survivor than those treated with serial amniocentesis.
CONCLUSION: Our study suggests a relationship between perinatal morbidity and mortality rates and stage in serial amniocentesis but not in selective laser photocoagulation of communicating vessel-treated twin-twin transfusion syndrome patients. These findings could be used to tailor the treatment of twin-twin transfusion syndrome. A clinical trial to confirm these results is being organized by our research groups.

Entities:  

Mesh:

Year:  2003        PMID: 12748508     DOI: 10.1067/mob.2003.292

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  15 in total

Review 1.  Recent developments in fetal medicine.

Authors:  Sailesh Kumar; Anna O'Brien
Journal:  BMJ       Date:  2004-04-24

2.  A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome.

Authors:  Timothy M Crombleholme; David Shera; Hanmin Lee; Mark Johnson; Mary D'Alton; Flint Porter; Jacquelyn Chyu; Richard Silver; Alfred Abuhamad; George Saade; Laurence Shields; David Kauffman; Joanne Stone; Craig T Albanese; Ray Bahado-Singh; Robert H Ball; Larissa Bilaniuk; Beverly Coleman; Diana Farmer; Vickie Feldstein; Michael R Harrison; Holly Hedrick; Jeffrey Livingston; Robert P Lorenz; David A Miller; Mary E Norton; William J Polzin; Julian N Robinson; Jack Rychik; Per L Sandberg; Istvan Seri; Erin Simon; Lynn L Simpson; Larisa Yedigarova; R Douglas Wilson; Bruce Young
Journal:  Am J Obstet Gynecol       Date:  2007-10       Impact factor: 8.661

3.  Initial fetal cardiovascular profile score predicts recipient twin outcome in twin-twin transfusion syndrome.

Authors:  Amy D Shah; William L Border; Timothy M Crombleholme; Erik C Michelfelder
Journal:  J Am Soc Echocardiogr       Date:  2008-06-16       Impact factor: 5.251

4.  Blood pressure evaluation in children treated with laser surgery for twin-twin transfusion syndrome at 2-year follow-up.

Authors:  Jay D Pruetz; Sheree M Schrager; Tiffany V Wang; Arlyn Llanes; Ramen H Chmait; Douglas L Vanderbilt
Journal:  Am J Obstet Gynecol       Date:  2015-05-21       Impact factor: 8.661

5.  Update in fetal cardiac intervention.

Authors:  Regina Viesca; James C Huhta
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-09

6.  Prevalence and risk factors of cerebral lesions in neonates after laser surgery for twin-twin transfusion syndrome.

Authors:  Douglas L Vanderbilt; Sheree M Schrager; Arlyn Llanes; Ramen H Chmait
Journal:  Am J Obstet Gynecol       Date:  2012-10       Impact factor: 8.661

7.  Diastolic Cardiac Pathology and Clinical Twin-Twin Transfusion Syndrome in Monochorionic/Diamniotic Twins.

Authors:  Anita J Moon-Grady; Larry Rand; Salvador Gallardo; Kristen Gosnell; Hanmin Lee; Vickie A Feldstein
Journal:  Am J Obstet Gynecol       Date:  2011-09-01       Impact factor: 8.661

8.  Selective fetoscopic laser photocoagulation of superficial placental anastomoses for the treatment of severe twin-twin transfusion syndrome.

Authors:  Rodrigo Ruano; Maria de Lourdes Brizot; Adolfo Wenjaw Liao; Marcelo Zugaib
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 9.  Understanding Sociodemographic Disparities in Maternal-Fetal Surgery Study Participation.

Authors:  Abigail Wilpers; Anna Y Lynn; Barbara Eichhorn; Amy B Powne; Megan Lagueux; Janene Batten; Mert Ozan Bahtiyar; Cary P Gross
Journal:  Fetal Diagn Ther       Date:  2022-03-10       Impact factor: 2.208

10.  A case of successful selective abortion using radio-frequency ablation in twin pregnancy suffering from severe twin to twin transfusion syndrome.

Authors:  Eun-Mi Chang; Mi-Hye Park; Young-Ju Kim; Jong-Il Kim; Jung-Ja Ahn; Sun-Hee Chun
Journal:  J Korean Med Sci       Date:  2009-06-16       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.